Pulmatrix, INC 10-Q quarterly reports

Pulmatrix, Inc. reported a net loss for the quarter ended June 30, 2026, and faces substantial doubt about its ability to continue as a going concern without the successful completion of its proposed merger with Eos.

Pulmatrix, Inc. reported its Q1 2026 results, detailing a proposed merger with Eos SENOLYTIX, Inc. and concurrent private financings totaling $19 million.

Pulmatrix reports Q3 2025 results, highlighting significant financial shifts and ongoing uncertainty surrounding its proposed merger with Cullgen Inc. and the need for regulatory approval.

Pulmatrix, a biopharmaceutical company, reported a reduced net loss in Q2 2025, driven by lower operating expenses, as its proposed merger with Cullgen Inc. faces a 60-day extension due to pending Chinese regulatory approval.

Pulmatrix reports its Q1 2025 financial results while navigating a planned merger with Cullgen and exploring opportunities to monetize existing clinical assets.

Pulmatrix's Q3 2024 results show a revenue increase due to a contract modification with Cipla, alongside reduced operating expenses following a strategic transaction with MannKind.

Pulmatrix has entered into agreements with MannKind Corporation to sell its lab assets, assign its lease, and cross-license intellectual property, marking a significant strategic shift for the company.

Pulmatrix, Inc. reported a significant increase in revenue for the first quarter of 2024, primarily due to a contract modification related to their Cipla agreement, while also detailing progress in their clinical programs.